CPH vs. CRON, THCX, GUD, ACB, WEED, FIRE, OGI, EPI, ICC, and RIV
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include Cronos Group (CRON), Hydropothecary (THCX), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), ICC Labs (ICC), and RIV Capital (RIV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Cipher Pharmaceuticals vs.
Cronos Group (TSE:CRON) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Cipher Pharmaceuticals received 112 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 62.20% of users gave Cipher Pharmaceuticals an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
Cronos Group has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Cipher Pharmaceuticals has a net margin of 102.01% compared to Cronos Group's net margin of -56.43%. Cipher Pharmaceuticals' return on equity of 28.43% beat Cronos Group's return on equity.
Cronos Group currently has a consensus target price of C$3.18, indicating a potential upside of 11.19%. Cipher Pharmaceuticals has a consensus target price of C$12.50, indicating a potential downside of 11.97%. Given Cronos Group's higher possible upside, research analysts clearly believe Cronos Group is more favorable than Cipher Pharmaceuticals.
Cipher Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
16.0% of Cronos Group shares are held by institutional investors. Comparatively, 1.4% of Cipher Pharmaceuticals shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.
Summary
Cipher Pharmaceuticals beats Cronos Group on 13 of the 17 factors compared between the two stocks.
Get Cipher Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cipher Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:CPH) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CPH Stock Alerts